
DarioHealth (DRIO) Stock Forecast & Price Target
DarioHealth (DRIO) Analyst Ratings
Bulls say
DarioHealth is a virtual chronic care company that has shown sequential growth in revenue driven by channel partner traction and expansion into musculoskeletal conditions. The company aims to reach break-even cash flow by 4Q26/1Q27, which is reasonable given their focus on cost management and potential new partnerships with hospital systems. However, challenges such as limited growth visibility, potential churn of customers, and the need for further capital raises may hinder their revenue growth and profitability.
Bears say
DarioHealth is performing well in terms of revenue, with a 1Q revenue of $5.6M that beat the estimated $5.3M, driven by strong B2C revenue from MSK solutions and international growth. The company's goal of reaching cash flow breakeven by mid-2027 is also on track, with expansion of the customer pipeline to $127M. However, there are potential risks in the HCIT space, such as government program cuts and constrained hospital budgets, which could impact spending on HCIT. Additionally, increased competition and delays in purchasing decisions for non-EHR related solutions could also pose challenges for DarioHealth.
This aggregate rating is based on analysts' research of DarioHealth and is not a guaranteed prediction by Public.com or investment advice.
DarioHealth (DRIO) Analyst Forecast & Price Prediction
Start investing in DarioHealth (DRIO)
Order type
Buy in
Order amount
Est. shares
0 shares